LDS/Medical Tests/Kell K/k Antigen (KEL) Genotyping

Kell K/k Antigen (KEL) Genotyping

The K antigen is the third most immunogenic antigen after the antigens of the ABO and Rh blood group systems. It cleaves big endothelin-3 to ET-3, a potent vasoconstrictor. The highly polymorphic Kell gene (KEL) contains several alleles that encode 25 antigens that define the Kell blood group. K (Kell) and k (Cellano) alleles are the most common. A single base change in exon 6 is the difference between K and k. The possible red blood cell phenotypes are K-k+, K+k+, K+k- with 91.1%, 8.7%, and 0.2% frequencies respectively; these are the most clinically important phenotypes.

Anti-K (mostly IgG) has been the cause of severe hemolytic disease of the fetus and newborn (HDFN) and hemolytic transfusion reactions (HTR). In about 10% of cases anti-K production has been observed by transfusion of K-positive blood to K-negative individuals. In neonates, the cause of hemolysis is the suppression of erythropoiesis rather than immune destruction of mature fetal erythrocytes. In this case, hyperbilirubinemia is milder, as less mature cells with less hemoglobin content are lysed. It is recommended that K-negative blood should be transfused to females of childbearing age. In some cases, with K-positive spouse, PCR of amniocyte DNA is the method of choice for the fetal K type determination. Cell-free fetal DNA in the plasma of pregnant women presents a noninvasive method to determine the fetal blood group genotype. Anti-k is a very rare antibody with history of mild HDFN.

The KEL gene is located on chromosome 7q33. The most common mutation on the KEL gene is point mutation C>T at KEL position 578 which results in an amino acid substitution Thr193 (k) to Met193 (K). Autosomal dominant inheritance; K-positive phenotypes result from heterozygosity or homozygosity for K.

  • Screening to prevent hemolytic transfusion reactions
  • Screening for prevention of hemolytic disease of the fetus and newborn
  • As an aid in diagnosis of autoimmune hemolytic anemia
  • Fetal testing when the mother has clinically significant alloantibody and the father of the pregnancy is either heterozygous for K or not available for testing
  • Paternal testing in a K RBC antigen-positive individual to determine K heterozygosity or homozygosity when his reproductive partner is K-negative by RBC antigen typing
K-negative genotyping predicts a K-negative phenotype. K-homozygous or heterozygous by genotyping predicts a K-positive phenotype. Mutation on the *KEL* gene often results to lacking/absence of the antigen, which usually leads to development of antibodies against Kell antigens when transfused with blood containing that antigen. Subsequent blood transfusions may be marked by destruction of the new cells by these antibodies, a process known as hemolysis. People without Kell antigens (K0), must be transfused with blood from donors who are also K0 to prevent hemolysis.

Mutation not detected

 

 

PCR-SSP (PCR amplification with sequence-specific primers), Real-time PCR with melting point analysis, DNA genotyping by Bead Chip array, PCR with FRET detection and melting point analysis, conventional sequencing, pyrosequencing.

Whole blood (EDTA, Citrate)

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Indirect Coombs test, Antigen Testing, AHG-Specific Individual RBC Antigen, Rh antigen genotyping, RhCc Antigen (*RHCE*) Genotyping, RhEe Antigen (*RHCE*) Genotyping.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login